March 14, 2013 – FDA announces that it is evaluating findings which suggest an increased risk of pancreatitis and pre-cancerous cellular changes (pancreatic duct metaplasia) associated with incretin mimetics.
March 14, 2013 – FDA announces that it is evaluating findings which suggest an increased risk of pancreatitis and pre-cancerous cellular changes (pancreatic duct metaplasia) associated with incretin mimetics.